Comparison of Microvascular Inflammation in Renal Allograft Tissue between ABO Incompatible and ABO Compatible Kidney Transplantation

E. Ko,^1,2 B. Choi,^1,2 C. Park,^1,2 Y. Kim,^1,2 C. Yang,^1,2 B. Chung.^1,2

¹Transplant Research Center, College of Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
²Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

Meeting: 2018 American Transplant Congress

Abstract number: A111

Keywords: Kidney, Rejection

Session Information

Session Name: Poster Session A: Kidney Acute Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, June 2, 2018

Session Time: 5:30pm-7:30pm

Presentation Time: 5:30pm-7:30pm

Location: Hall 4EF

Background: Microvascular inflammation (MVI) is considered as a pathological marker for antibody-mediated rejection (AMR) in the presence of donor-specific antibody (DSA). We aimed to investigate clinical role of MVI as predicting AMR in ABO incompatible kidney transplantation. (ABOi KT)

Material and Methods: A single-center retrospective matched cohort study was conducted. We evaluated histologic parameters in kidney biopsy of 296/75 ABO compatible (ABOc)/ABO incompatible (ABOi) consecutive living donor KT, matched for donor age and transplantation year. In the ABOi group, the desensitization protocol consisted of rituximab, plasmapheresis and immunoglobulins.

Results: Between ABOc and ABOi group, there was no difference in death-censored graft survival, and patient survival. (p-values for each 0.068. and 0.294) The cumulative incidence of acute rejection determined by both protocol biopsy and indication biospies was 19.5% and 23.2% (p=0.515) There was no difference in the incidence of MVI between ABOi KT and ABOc KT. (p=0.284) The incidence of MVI at protocol biopsy on post KT 3 months were not statistically different between ABOi and ABOc group. (p=0.103) High titer of Anti-A/B antibody didn't correlated with the risk of MVI. (p=0.689) When compare ABOi KT to human leukocyte antigen (HLA) sensitized KT, highly-HLA-sensitized group (DSA Luminex MFI >5,000 or Pannel reactive antibody (PRA)>50%) showed tendency of increased rejection rate compared to low-sensitized group, despite of statistically insignificance. (p=0.311) And highly sensitized ABOi group had more frequently incidence of MVI than low-sensitized group (p<0.001).

Conclusion: In contrast to HLA-DSA, ABO incompatibility or anti-A/B antibody titer was not associated with the development of MVI in allograft tissue.

CITATION INFORMATION: Ko E., Choi B., Park C., Kim Y., Yang C., Chung B. Comparison of Microvascular Inflammation in Renal Allograft Tissue between ABO Incompatible and ABO Compatible Kidney Transplantation Am J Transplant. 2017;17 (suppl 3).

To cite this abstract in AMA style:

Ko E, Choi B, Park C, Kim Y, Yang C, Chung B. Comparison of Microvascular Inflammation in Renal Allograft Tissue between ABO Incompatible and ABO Compatible Kidney Transplantation [abstract]. https://atcmeetingabstracts.com/abstract/comparison-of-microvascular-inflammation-in-renal-allograft-tissue-between-abo-incompatible-and-abo-compatible-kidney-transplantation/. Accessed June 6, 2025.

« Back to 2018 American Transplant Congress